PeptiDream, Inc. is a Japanese pharmaceutical company with a ESG risk rating score of 21.5, indicating a medium risk assessment. Specializing in the research and development of new pharmaceutical candidates, PeptiDream discovers constrained peptides, small molecules, and peptide-drug conjugate therapeutics through its innovative Peptide Discovery Platform System. The company aims to lead in drug discovery and development to provide solutions for unmet medical needs and enhance the well-being of patients globally.